Today: 22 March 2026
Subscribe
Browse Category

NYSE:LLY 24 November 2025 - 9 December 2025

Eli Lilly (LLY) Stock on December 9, 2025: Jaypirca Breakthrough, Adverum Deal and Zepbound Price Cuts Reframe the Outlook

Eli Lilly (LLY) Stock on December 9, 2025: Jaypirca Breakthrough, Adverum Deal and Zepbound Price Cuts Reframe the Outlook

Eli Lilly shares traded near $997 early Monday, about 10% below last month’s record high. The company released Phase 3 data showing Jaypirca cut disease progression risk by 80% in untreated CLL/SLL, closed its Adverum Biotechnologies acquisition, and raised its quarterly dividend 15% to $1.73. Lilly also cut Zepbound prices and reported Q3 revenue up 54% to $17.6 billion.
9 December 2025
Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly shares closed at $998 on December 8, down 1.3%, marking a seventh straight decline and leaving the stock about 10% below its recent high. The company reported a 15% dividend increase, secured Chinese reimbursement for Mounjaro, and saw Nobel laureate Carolyn Bertozzi return to its board. Competition and price cuts in weight-loss drugs weighed on the stock.
9 December 2025
······
Eli Lilly (LLY) Stock on December 8, 2025: China Insurance Win, Trillion‑Dollar Status and What Comes Next for Investors

Eli Lilly (LLY) Stock on December 8, 2025: China Insurance Win, Trillion‑Dollar Status and What Comes Next for Investors

Eli Lilly shares traded near $1,010 Monday, keeping its valuation close to $1 trillion after surging demand for GLP-1 drugs. China will add Mounjaro to its state insurance list from January 2026, opening a large market but at lower prices. U.S. price cuts and political pressure weigh on margins. Q3 revenue jumped 54% to $17.6 billion, with analysts citing high growth expectations and a premium valuation as risks.
8 December 2025
·
Eli Lilly (LLY) Stock: Key Catalysts to Watch Before the Market Opens on December 8, 2025

Eli Lilly (LLY) Stock: Key Catalysts to Watch Before the Market Opens on December 8, 2025

Eli Lilly shares closed Friday at $1,010.31, down 0.41%, before edging higher after hours. The stock sits about 9% below its late-November record high. Over the weekend, China added Lilly’s Alzheimer’s drug Kisunla to a new insurance list for high-priced therapies, offering improved market access with smaller price cuts than usual. Investors await Monday’s session for reaction.
7 December 2025
··
Eli Lilly (LLY) Stock on 6 December 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Forecasts

Eli Lilly (LLY) Stock on 6 December 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Forecasts

Eli Lilly shares traded near $1,010 on December 6, 2025, with a market value just under $1 trillion after a brief pullback from record highs. The company cut list prices on Zepbound vials this week, pressuring margins and sending the stock lower. Zepbound and Mounjaro generated $10.1 billion in Q3 sales, making Lilly’s GLP-1 drugs the world’s top-selling franchise. Most analysts maintain Buy ratings, with 12-month targets around $1,060–$1,090.
6 December 2025
···
Eli Lilly (LLY) Stock Outlook: Can the Obesity-Drug Giant Keep Justifying a $1,000 Share Price?

Eli Lilly (LLY) Stock Outlook: Can the Obesity-Drug Giant Keep Justifying a $1,000 Share Price?

Eli Lilly shares traded above $1,000 on December 5, 2025, after recently crossing a $1 trillion market cap, the first for a healthcare company. The stock is up over 30% year to date despite an 8% pullback in the past week. Lilly is cutting prices on its obesity drug Zepbound and preparing to seek accelerated approval for a new weight-loss pill. The company’s dividend yield remains around 0.6%.
5 December 2025
··
Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly shares traded near $1,060 midday December 2, just below record highs, after a year of sharp gains fueled by obesity and diabetes drugs. The company cut U.S. self-pay prices for Zepbound on December 1, following a federal deal to lower GLP-1 prices. Lilly’s market cap briefly topped $1 trillion in November, the first for a healthcare firm. WHO issued its first guideline recommending GLP-1 drugs for obesity on December 1.
2 December 2025
··
Eli Lilly (LLY) Stock on December 1, 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Outlook

Eli Lilly (LLY) Stock on December 1, 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Outlook

Eli Lilly shares traded near $1,075 on December 1, 2025, giving the company a market cap of about $1.02 trillion, the first for a pharmaceutical firm. The company cut prices on its obesity drug Zepbound, lowering the starting dose to $299 per month from $349. Lilly’s GLP-1 drugs generated over $10 billion in Q3 revenue. The stock trades at over 70 times trailing earnings.
1 December 2025
··
Eli Lilly (LLY) Stock Outlook Before Market Open on December 1, 2025: Trillion‑Dollar Rally Pauses After Policy Shock

Eli Lilly (LLY) Stock Outlook Before Market Open on December 1, 2025: Trillion‑Dollar Rally Pauses After Policy Shock

Eli Lilly shares closed at $1,075.47 on Friday, down 2.6% after a month-long rally that briefly pushed its market value above $1 trillion. The stock remains up about 39% year-to-date and surged roughly 26–31% in November, driven by demand for its obesity drugs. Investors are weighing recent policy headlines and valuation concerns ahead of Monday’s open. No pre-market quote was available with US markets closed over the weekend.
30 November 2025
··
Eli Lilly Stock on November 30, 2025: Trillion‑Dollar Pharma, GLP‑1 Boom and Valuation Jitters Around LLY

Eli Lilly Stock on November 30, 2025: Trillion‑Dollar Pharma, GLP‑1 Boom and Valuation Jitters Around LLY

Eli Lilly closed Friday at $1,075 per share, capping a November surge that pushed its market value above $1 trillion—the first for a pharmaceutical company. Shares rose about 26% in November and are up over 40% in 2025. Investors are debating whether the stock, trading at a trailing P/E of 70, can sustain further gains amid strong demand for its GLP-1 obesity drugs.
30 November 2025
··
Eli Lilly (LLY) Stock Today: Trillion‑Dollar Weight‑Loss Giant Pulls Back After November Surge

Eli Lilly (LLY) Stock Today: Trillion‑Dollar Weight‑Loss Giant Pulls Back After November Surge

Eli Lilly shares closed at $1,075.47 on November 28, down 2.6%, pulling the S&P 500 healthcare sector lower despite gains in the broader market. The stock remains up over 30% for November and more than 40% year-to-date, with a market cap around $1 trillion. JPMorgan raised its price target to $1,150. Recent gains followed strong Q3 earnings and surging sales of Mounjaro and Zepbound.
29 November 2025
··
Eli Lilly (LLY) Stock Dips After Trillion‑Dollar Surge: November 29, 2025 Update for Investors

Eli Lilly (LLY) Stock Dips After Trillion‑Dollar Surge: November 29, 2025 Update for Investors

Eli Lilly shares fell 2.61% to about $1,075.47 on November 29, 2025, continuing a pullback from record highs reached earlier in the month. The company’s market cap stands near $989 billion, with shares still up roughly 43% for the year after a surge fueled by strong Q3 results and demand for obesity drugs. Trading volume was around 2.73 million shares. The stock remains priced at a P/E ratio above 50.
29 November 2025
··
Eli Lilly (LLY) Stock Today, November 28, 2025: Post–$1 Trillion Milestone, Is the Rally Catching Its Breath?

Eli Lilly (LLY) Stock Today, November 28, 2025: Post–$1 Trillion Milestone, Is the Rally Catching Its Breath?

Eli Lilly shares fell about 2.5% to $1,077 in light trading Friday, a week after becoming the first drugmaker to hit a $1 trillion market value. The stock remains up 33% year-to-date and trades near its record high. Mounjaro and Zepbound drove over $10 billion in quarterly sales, more than half of company revenue. Lilly recently reached a deal with the U.S. government to expand access to its obesity drugs.
28 November 2025
·
Stock Market Today, November 26, 2025: Dow Futures Rise On Fed Rate-Cut Bets As Nvidia, Apple, Bitcoin And Eli Lilly Take Center Stage

Stock Market Today, November 26, 2025: Dow Futures Rise On Fed Rate-Cut Bets As Nvidia, Apple, Bitcoin And Eli Lilly Take Center Stage

U.S. stock futures rose early Wednesday, with Dow, S&P 500, and Nasdaq futures up 0.2%–0.35% as traders bet on a December Fed rate cut. Nvidia and AMD slipped on news of an Alphabet–Meta AI chip partnership. Apple gained after a rebound in China iPhone sales. Eli Lilly hovered near a $1 trillion valuation on strong demand for weight-loss drugs.
26 November 2025
·····
Eli Lilly (LLY) Stock Today: $1 Trillion Pharma Giant Extends Rally on Bernstein Upgrade and GLP‑1 Momentum – 25 November 2025

Eli Lilly (LLY) Stock Today: $1 Trillion Pharma Giant Extends Rally on Bernstein Upgrade and GLP‑1 Momentum – 25 November 2025

Eli Lilly shares closed at $1,092.4 on Tuesday, up over 2%, after Bernstein raised its price target to $1,300 citing optimism for the obesity drug orforglipron. The stock’s market value stands near $1 trillion, with shares up more than 50% in three months and trading above the average analyst target. Trading volume was about 1.2 million shares.
25 November 2025
··
Eli Lilly (LLY) Stock Today, November 24, 2025: Trillion‑Dollar Milestone, $1,300 Price Target and New Weight‑Loss Shot Data

Eli Lilly (LLY) Stock Today, November 24, 2025: Trillion‑Dollar Milestone, $1,300 Price Target and New Weight‑Loss Shot Data

Eli Lilly shares traded near $1,070 Monday, up 0.9%, with market cap around $960 billion after briefly topping $1 trillion last week—the first healthcare firm to do so. Bernstein raised its price target to $1,300, citing strong obesity drug prospects. Novo Nordisk’s Alzheimer’s trial failure shifted GLP-1 sentiment. Lilly reported new Phase 2 weight-loss drug data showing up to 20% body-weight reduction.
24 November 2025
·
Eli Lilly Hits $1 Trillion: Weight‑Loss Drugs Turn a 150‑Year‑Old Pharma Into a Tech‑Sized Giant

Eli Lilly Hits $1 Trillion: Weight‑Loss Drugs Turn a 150‑Year‑Old Pharma Into a Tech‑Sized Giant

Eli Lilly became the first pharmaceutical company to reach a $1 trillion market capitalization, with shares trading near $1,058 on Monday. The surge follows strong demand for its weight-loss and diabetes drugs Mounjaro and Zepbound, both based on tirzepatide. Lilly’s stock has climbed over 35% in 2025 and more than 75% since Zepbound’s late 2023 launch. The company now trades at about 50 times expected earnings.
24 November 2025
···
1 … 7 8 9 10 11 12

Stock Market Today

  • SATS Ltd Stock Impacted by Slowdown in Asia Aviation Recovery
    March 22, 2026, 11:52 AM EDT. SATS Ltd faces headwinds as the aviation recovery in Asia slows down, affecting its stock performance. The company, a key player in aviation services, is experiencing pressure amid fluctuating air travel demand in the region. Investors are cautious due to the uncertain pace of rebound in passenger volumes. SATS Ltd's financial outlook is challenged by external factors slowing the sector's recovery momentum, leading to market volatility for its shares. This development highlights the difficulties still faced by airlines and related service providers in Asia's post-pandemic landscape.
Go toTop